Fatima Naureen, Patel Sanket, Hussain Tahir
Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, United States.
Front Pharmacol. 2021 Apr 15;12:600163. doi: 10.3389/fphar.2021.600163. eCollection 2021.
Acute kidney injury (AKI) due to endotoxemic insult is predicted by the infiltration of neutrophils, monocytes and macrophages, and the release of pro-and anti-inflammatory cytokines to the site of injury. Earlier, we have demonstrated the role of angiotensin-II type 2 receptor (AT2R) stimulation in reno-protection in lipopolysaccharide (LPS)-induced inflammation and AKI in C57BL6/NHsd mice. Moreover, AT2R activation has been shown to increase the anti-inflammatory cytokine interleukin-10 (IL-10), its role in AT2R-mediated anti-inflammation and reno-protection is unknown. To address this question, in the present study mice were treated with the AT2R agonist C21 (0.3 mg/kg, intraperitoneally), LPS (5 mg/kg, intraperitoneally), or LPS with C21 pre-treatment with or without neutralizing IL-10 antibody. Treatment with C21 alone caused an increase in the plasma and kidney IL-10 levels, which peaks at 2-h, and returned to baseline at 6-h. The C21-induced IL-10 increase was blocked by the AT2R antagonist PD123319 suggesting AT2R's involvement. LPS treatment caused a profound increase in tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) and the LPS-induced increase in these cytokines was attenuated by the C21 pre-treatment (1-h prior LPS) both in the plasma and kidney. Neutralizing IL-10 antibody treatment abrogated the C21-lowering of TNF-α and IL-6 in the kidney but not in the plasma. Similar results as related to the cytokines profiles in all the groups were also observed in the heart and spleen. The alteration in early cytokine profile prompted us to measure the markers of renal function (blood urea nitogen and urinary creatinine) in order to analyze the effect of IL-10 neutralization. However, it was too early to observe changes in renal function. Therefore, the renal function and injury markers were again measured at 24 h. Treatment with neutralizing IL-10 antibody attenuated the C21-mediated improvement in indices of the kidney function, but not the biomarkers of renal injury (kidney injury molecule-1 and neutrophil-gelatinase associated lipocalin). Collectively, our data suggest that the involvement of IL-10 in AT2R-mediated anti-inflammation and reno-protection against LPS is complex, mediating the renal cytokine profile and kidney filtration function, but not the plasma cytokine profile and renal injury markers.
内毒素血症性损伤所致的急性肾损伤(AKI)可通过中性粒细胞、单核细胞和巨噬细胞的浸润以及促炎和抗炎细胞因子向损伤部位的释放来预测。此前,我们已证明在C57BL6/NHsd小鼠中,刺激血管紧张素II 2型受体(AT2R)在脂多糖(LPS)诱导的炎症和AKI的肾保护中发挥作用。此外,已表明AT2R激活可增加抗炎细胞因子白细胞介素10(IL-10),但其在AT2R介导的抗炎和肾保护中的作用尚不清楚。为解决这个问题,在本研究中,用AT2R激动剂C21(0.3 mg/kg,腹腔注射)、LPS(5 mg/kg,腹腔注射)或LPS预处理C21(有无中和IL-10抗体)对小鼠进行治疗。单独用C21治疗导致血浆和肾脏IL-10水平升高,在2小时达到峰值,并在6小时恢复到基线水平。AT2R拮抗剂PD123319阻断了C21诱导的IL-10升高,提示AT2R参与其中。LPS治疗导致肿瘤坏死因子-α(TNF-α)和白细胞介素-6(IL-6)大幅升高,C21预处理(LPS前1小时)可减轻血浆和肾脏中LPS诱导的这些细胞因子升高。中和IL-10抗体治疗消除了C21对肾脏中TNF-α和IL-6的降低作用,但对血浆中没有作用。在心脏和脾脏中也观察到了与所有组细胞因子谱相关的类似结果。早期细胞因子谱的改变促使我们测量肾功能标志物(血尿素氮和尿肌酐),以分析IL-10中和的效果。然而,观察肾功能变化还为时过早。因此,在24小时时再次测量肾功能和损伤标志物。用中和IL-10抗体治疗减弱了C21介导的肾功能指标改善,但未减弱肾损伤生物标志物(肾损伤分子-1和中性粒细胞明胶酶相关脂质运载蛋白)。总体而言,我们的数据表明,IL-10参与AT2R介导的抗炎和针对LPS的肾保护作用是复杂的,介导肾脏细胞因子谱和肾脏滤过功能,但不介导血浆细胞因子谱和肾损伤标志物。